High-Quality Anti-Estrogen Letrozole Femara (CAS: 112809-51-5)

• Post Date:

  Mar 20,2017

• Expiry Date:

  Mar 20,2018

• Detailed Description:

  Cas No. :112809-51-5 Quantity: 0.01Kilograms
  Payment Method: Western union ,monery gram ,Bitcoin
  Applications:
  Femara is a new drug developed for the treatment of advanced breast cancer in women. Femara is the second in a new class of third-generation selective oral aromatase inhibitors.
  It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen. Since many forms of breast cancer cells are stimulated by estrogen, it is hoped that by reducing amounts of estrogen in the body the progression of such a disease can be halted. This is the basic premise behind Nolvadex, except this drug blocks the action and not production of estrogen.
  The effects of Femara can be quite dramatic to say the least. A daily dose of one tablet (2.5 mg) can produce estrogen suppression greater than 80 % in treated patients. With the powerful effect this drug has on hormone levels, it is only to be used (clinically) by post-menopausal women whose disease has progressed following treatment with Nolvadex. Side effects like hot flushes and hair thinning can be present, and would no doubt be much more severe in pre-menopausal patients.
  Usage: Used as API in Treatment of breast disease.
  
  Email : alan@sinosteroids.com
  
  Website : www.sinosteroids.com

• CAS Registry Number:

  112809-51-5

• Synonyms:

  ;4,4'-(1h-1,2,4-Triazol-1-Ylmethylene)Bisbenzonitrile;Lelrozol;4,4'-(1h-1,2,4-Triazol-1-Ylmethylene) Bis-Benzonitrile;Femara;Letrozol;Letrazole;

• Molecular Formula:

  C₁₇H₁₁N₅

• Molecular Weight:

  285.31

• Molecular Structure:

  

• Company:

  HongKong Blue Universal     [ China ]        

• Contact:

  alan

• Tel:

  +86-170-76116742

• Fax:

• Email:

  alan@sinosteroids.com